Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries

OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical practice and to anchor these results with a general...

Descripción completa

Detalles Bibliográficos
Autores principales: Delcoigne, Benedicte, Ljung, Lotta, Provan, Sella A, Glintborg, Bente, Hetland, Merete Lund, Grøn, Kathrine Lederballe, Peltomaa, Ritva, Relas, Heikki, Turesson, Carl, Gudbjornsson, Bjorn, Michelsen, Brigitte, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120408/
https://www.ncbi.nlm.nih.gov/pubmed/35318218
http://dx.doi.org/10.1136/annrheumdis-2021-221996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120408/
https://www.ncbi.nlm.nih.gov/pubmed/35318218
http://dx.doi.org/10.1136/annrheumdis-2021-221996

Ejemplares similares